Disease · MONDO_0002465
bronchiolitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bronchiolitis. Diseases, record MONDO_0002465. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002465
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 15 | Drugs and targets |
| EPINEPHRINE | CHEMBL679 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| MAGNESIUM SULFATE | CHEMBL3989857 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ALBUTEROL SULFATE | CHEMBL1441059 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MONTELUKAST SODIUM | CHEMBL1200681 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYGEN | CHEMBL1234886 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PALIVIZUMAB | CHEMBL1201586 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PORACTANT ALFA | CHEMBL1201622 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| ZINC SULFATE | CHEMBL1200929 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets22
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 3 | Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | 2 | Cysteinyl leukotriene receptor 1 antagonist | Phase 3 | https://conductscience.org/library/genes/10800 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Unknown | https://conductscience.org/library/genes/3454 | Drugs and targets |
1 to 10 of 22
See all 22 targetsTrials54
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00619918 | Nebulized Hypertonic Saline for Bronchiolitis | Phase 2/3 | 447 | 2013-10-10 | Bronchiolitis | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01488448 | A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis | Not applicable | 227 | 2014-08-22 | Bronchiolitis | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00863317 | Trial of Montelukast for Treatment of Acute Bronchiolitis | Not applicable | 141 | 2015-06-19 | Bronchiolitis | MONTELUKAST | Its record names the disease | ClinicalTrials.gov |
| NCT01238848 | Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis | Not applicable | 82 | 2012-08-17 | Bronchiolitis | ALBUTEROL, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00116584 | Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients | Phase 3 | 72 | 2020-05-20 | Bronchiolitis | EPINEPHRINE, OXYGEN | Its record names the disease | ClinicalTrials.gov |
| NCT00435994 | Assessment of Airway Obstruction in Infants With Lower Respiratory Infections | Not applicable | 59 | 2016-06-01 | Bronchiolitis, Respiratory Syncytial Virus Infections | EPINEPHRINE | Its record names the disease | ClinicalTrials.gov |
| NCT02029040 | Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis | Not applicable | 52 | 2019-01-25 | Acute Bronchiolitis | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02469597 | Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis | Phase 2 | 46 | 2016-08-12 | Bronchiolitis | FUROSEMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02834819 | Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis | Not applicable | 18 | 2020-02-11 | Bronchiolitis | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00076973 | An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272) | Phase 3 | 1,125 | Bronchiolitis | MONTELUKAST SODIUM | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 54
See all 54 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nebulized 3% Saline vs Nebulized 0.9% Saline: Number of Participants With Supplemental Medication Use | 39 of 231 | 39 of 216 | 447 | NCT00619918 | Trial comparisons |
| Hypertonic Saline vs Normal Saline: deaths from any cause | 0 of 231 | 0 of 216 | 447 | NCT00619918 | Trial comparisons |
| Hypertonic Saline vs Normal Saline: serious adverse events | 0 of 231 | 0 of 216 | 447 | NCT00619918 | Trial comparisons |
| Hypertonic Saline vs Normal Saline: Clinical Worsening | 10 of 113 | 9 of 114 | 227 | NCT01488448 | Trial comparisons |
| Hypertonic Saline vs Normal Saline: serious adverse events | 13 of 113 | 10 of 114 | 227 | NCT01488448 | Trial comparisons |
| Nebulized Hypertonic Saline vs Nebulized Normal Saline: Readmission for Bronchiolitis Within 7 Days of Discharge | 4 of 93 | 3 of 97 | 190 | NCT01488448 | Trial comparisons |
| Montelukast vs Placebo: serious adverse events | 0 of 68 | 0 of 73 | 141 | NCT00863317 | Trial comparisons |
| Hypertonic vs Normal: serious adverse events | 0 of 50 | 0 of 50 | 100 | NCT01238848 | Trial comparisons |
| Heliox vs Oxygen: deaths from any cause | 0 of 34 | 0 of 35 | 69 | NCT00116584 | Trial comparisons |
| Heliox vs Oxygen: serious adverse events | 0 of 34 | 0 of 35 | 69 | NCT00116584 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials69
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002465
GET https://conductscience.org/api/diseases/v1/MONDO_0002465/drugs?page=2